OctreoPharm's OPS202 gets EMA orphan drug designation for management of GEP-NETs - 0 views
-
Alex Parker on 31 Jan 14Germany-based OctreoPharm Sciences has received Orphan Drug Designation from the European Medicines Agency (EMA) for OPS202 as a diagnostic agent for the management of patients with gastro-entero-pancreatic-neuroendocrine tumors